Blood:全外显子分析揭示基因对非血缘供体来源的血液骨髓移植后死亡率的影响

2018-04-03 MedSci MedSci原创

虽然存活预后显著提高,但仍有高达40%的患者死于HLA匹配的非血缘供体(URD)来源的血液和骨髓移植(BMT)后1年内。现有研究人员为明确非HLA遗传因素对BMT死亡率的影响,利用Illumina HumanExome BeadChip在DISCOVeRY-BMT队列中进行第一全外显子的关联研究。本研究包含2000年-2011年间进行治疗的2473位AML、ALL、MDS患者和2221位HLA10

虽然存活预后显著提高,但仍有高达40%的患者死于HLA匹配的非血缘供体(URD)来源的血液和骨髓移植(BMT)后1年内。

现有研究人员为明确非HLA遗传因素对BMT死亡率的影响,利用Illumina HumanExome BeadChip在DISCOVeRY-BMT队列中进行第一全外显子的关联研究。

本研究包含2000年-2011年间进行治疗的2473位AML、ALL、MDS患者和2221位HLA10/10匹配的供体。对于总体存活率(OS)、移植相关的死亡率(TRM)和疾病相关的死亡率(DRM)进行单变量和基因水平的分析。

若在睾丸表达的TEX38基因携带一种罕见的非同义突变时,供受体之间基因型不匹配可显增著TRM的风险,而且在受体或供体是女性时,风险增加更为明显。

利用SKAT-O试验来评估基因水平效应,受体为OR51D1突变型与OS和TRM显著相关。对于供体,四个(ALPP、EMID1、SLC44A5、LRP1)、一个(HHAT)和两个(LYZL4、NT5E)基因分别与OS、TRM和DRM显著相关。对NT5E晶体结构的检测表明4种相关突变影响酶的结构,并可能会降低酶的催化效应。

进一步证实上述发现和其他功能性研究或许可为我们提供个体化的风险预测和预后估计,也可能会改变供体的筛选方案。

原始出处:

Qianqian Zhu,et al.Exomechip Analyses Identify Genes Affecting Mortality after HLA-Matched Unrelated Donor Blood and Marrow Transplantation.Blood  2018  :blood-2017-11-817973;  doi: https://doi.org/10.1182/blood-2017-11-817973

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-07-16 feather85
  3. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 sunfeifeiyang

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 神功盖世

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1812566, encodeId=55691812566ce, content=<a href='/topic/show?id=9af38989368' target=_blank style='color:#2F92EE;'>#血缘供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89893, encryptionId=9af38989368, topicName=血缘供体)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Dec 31 05:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631856, encodeId=d8ae1631856f9, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Mon Jul 16 06:15:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619041, encodeId=ec9c1619041bb, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 05 04:15:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302670, encodeId=585c3026e038, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Apr 04 11:08:03 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302665, encodeId=645c3026655b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Apr 04 11:06:20 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302378, encodeId=6a653023e832, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Apr 03 13:31:26 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 sunfeifeiyang

    0

相关资讯

白血病你站住,你知道自己治疗费用多少吗?

白血病,是恶性血液系统疾病,也被老百姓们俗称为“血魔”。白血病是一类造血干细胞恶性克隆性疾病。克隆性白血病细胞因为增殖失控、分化障碍、凋亡受阻等机制在骨髓和其他造血组织中大量增殖累积,并浸润其他非造血组织和器官,同时抑制正常造血功能。临床可见不同程度的贫血、出血、感染发热以及肝、脾、淋巴结肿大和骨骼疼痛。关于这个病的治疗费用,往往令患者与其家属望而却步,也有人认为治疗白血病的费用是一个“无底洞”。

Blood:基因突变导致了骨髓衰竭对骨髓移植的无应答

研究者报到了来自三个无关家庭的5位已经进展到三系骨髓衰竭的严重血小板减少症患者的治疗情况,并发表在最新一期的Blood杂志上。

男童患罕见石骨症,医生爸爸:救无数人却救不了儿子

“骨头是土壤,为生命的成长提供了可能。当石骨症儿童的骨骼钙化为岩石,他们的生命像石头缝里挤出来的花草,脆弱、艰难。”

Stem cells:年老的造血干细胞可通过与年轻的干细胞相互作用而重返年轻!

在骨髓移植中,供体的年龄是一个重要的关注点,因为年老的造血干细胞(HSCs)移植效率相对较低。研究人员通过小鼠系统发现,年老的HSCs与年幼的间充质干细胞(MSCs)短暂的相互作用,可通过细胞间转移含有自噬相关的mRNAs的微型囊泡(MVs)而使年老的HSCs年轻化、恢复细胞功能,同时MSCs的AKT信号被激活,出现老化。激活的AKT会减少细胞微型囊泡内的自噬相关的mRNAs,并将miR-17和m

JCO:血液恶性肿瘤移植治疗,骨髓移植vs外周血移植

正HLA单倍型相合造血干细胞移植(human leukocyte antigen-haploidentical hematopoietic stem cell transplantation,HLA-haplo HSCT)是大多数血液病患者可选择的一种移植方式,能够节约寻找供者的时间和花费。二十多年以来,多种单倍型相合移植方式,包括保留或去除T细胞的单倍型移植显示出了较好的预后。为了预防移植抗宿主

黄晓军:2017年度造血干细胞移植研究进展回顾

骨髓移植(即:造血干细胞移植,HSCT)是根治血液系统恶性疾病的有效方法之一。近年来,随着在世界范围内,单倍体相合造血干细胞移植(Haplo-HSCT)技术的迅速发展,已经基本解决了供者来源匮乏的问题,使每个需要接受HSCT的患者都能够找到合适的供者。并且,随着Haplo-HSCT体系的不断优化,其已经成为人类白细胞抗原(HLA)相合同胞移植、无关供者移植及脐血移植之外的一种重要移植手段。